Floatz logo

Montanide Isa 51

Carcinoma, Non-Small-Cell Lung

National Cancer Institute (NCI)Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
65/ 100

Competitive context

113 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / SponsorPhaseRating
Lazertinib
Janssen Research & Development, LLC
Phase 3BB
Cetuximab
Novartis Pharmaceuticals
Phase 3BB
DEXAMETHASONE
Rigshospitalet, Denmark
Phase 4BB
Vibostolimab
Merck Sharp & Dohme LLC
Phase 3BB
Vinorelbine
Guangzhou Institute of Respiratory Disease
Phase 3BB

View all 50 →

Same molecule, other indications

Montanide Isa 51 is also rated in:

Acute Myelogenous Leukemia (AML)Dormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →
melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →